Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XERXES rectal cancer neoadjuvant cetuximab + capecitabine chemoradiotherapy study
2004-001926-26Phase 2Completed
- Sponsor
- University College London
- Start
- Jun 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and capecitabine in rectal adenocarcinoma, sponsored by University College London. Primary endpoints: Acute toxicity and Safety and toxicity of erbitux, capecitabine and radiotherapy combination. Started Jun 2005; status: completed.
02
Drugs
cetuximabcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2004-001926-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001926-26.